65,437 trials
Rhinitis, Allergic, Perennial
Primary: Change From Baseline in the Total Nasal Symptom Score at 2 Weeks — -3.9850; -1.9081 score on a scale — p=<0.0001
Herpes Simplex Infection
Primary: Number of Subjects With Newly Acquired Genital Herpes Disease, Caused by Either Herpes Simplex Virus (HSV)-1 or HSV-2 — 35; 35 Subjects
Type 2 Diabetes Mellitus
Primary: Incremental Post-prandial 4-hour Weighted Mean Active Glucagon-like Peptide-1 (GLP-1) Plasma Concentrations — 6.00; 4.09; 7.22; 1.55 picomolar
Ovarian Cancer
Primary: Progression Free Survival (PFS) as Determined by the Investigator, Per Response Evaluation Criteria for Solid Tumors (RECIST) — 12.4; 8.4 Months — p=<0.0001
Chemotherapy-Induced Nausea and Vomiting (CINV)
Primary: Brain NK1-receptor Occupancy at 24 Hours Post Dose — 100.40; 100.20 Percent of occupancy
Fibromyalgia, Primary · Fibromyalgia, Secondary
Primary: Change From Baseline to 12-Week Endpoint in the Brief Pain Inventory (BPI) "24-Hour Average Pain" Item (Question 3) of the BPI-Modified Short Form Score — -2.04; -1.70…
Relapsed or Refractory Multiple Myeloma
Primary: Kaplan Meier Estimate for Time to Disease Progression — 214.0 days
Pelvic Inflammatory Disease
Primary: Response Rate (Clinical Response, Data Review Committee Assessment) in Participants Who Enrolled After Protocol Amendment (the Inclusion Criterion Regarding Fever of 37℃…
Asthma
Primary: Total Number of Asthma Exacerbations Reported During the Treatment Period — 24; 25 Number of asthma exacerbations — p=0.928
Multiple Sclerosis
Primary: The Occurrence of ≥ 3 New T2 Lesions With or Without Gd+ Enhancement or Clinical Exacerbation Through 12 Months. — 26; 18 Participants — p=0.929
Febrile Neutropenia
Primary: Percentage of Participants Receiving Antibacterial Agents Preferred by the Turkish Centers Monitoring Febrile Neutropenia (FEN) in Their Therapeutical Approach…
Varicella · Herpes Zoster
Primary: Number of Participants With an Occurrence of Breakthrough Varicella — 1425; 362; 28 Participants
Non-Small Cell Lung Cancer
Primary: Overall Survival (OS) Among All Randomized Patients — 9.3; 9.2 months — p=0.7583
West Nile Fever
Primary: Geometric Mean Titers (GMTs) of Antibodies to Vaccination With ChimeriVax™ WN02 or a Placebo Vaccine — 5.00; 5.76; 5.06; 5.22 Titers
Acute Coronary Syndrome
Primary: Adenosine Diphosphate (ADP)-Induced P2Y12 Receptor-mediated Platelet Aggregation (P2Y12 Reaction Units; PRU) Using the Accumetrics VerifyNow (VN) P2Y12 Assay at 4 Hours…